IMP3, a Promising Prognostic Marker in Clear Cell Renal Cell Carcinoma

Park, Ji Young; Choe, Mi Sun; Kang, Yuna; Lee, Sang Sook

doi:10.4132/koreanjpathol.2014.48.2.108

Cited by 7 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IMP3 expression has been associated with tumor formation, invasion, metastases, and cell proliferation (Ki-67-expression). Correlation between IMP3 expression and prognosis has also been established [34,35]. Similar correlations were found in our study with the melanoma xenograft mouse model that has not been previously published.…”

Section: Discussionsupporting

confidence: 90%

IMP3 Immunohistochemical Expression Is Related with Progression and Metastases in Xenografted and Cutaneous Melanomas

Martin-Morales,

Padial-Molina,

Tovar

et al. 2023

Pathobiology

View full text Add to dashboard Cite

Introduction: Insulin-like growth factor-II messenger RNA (mRNA)-binding protein-3 (IMP3) over-expression is a predictor of tumor recurrence and metastases in some types of human melanoma. Our objective is to evaluate the immunohistochemical expression of IMP3 and other molecules related to tumor prognosis in melanoma-xeno-tumors undergoing treatment. Material and methods: We inoculated A375 and G361 human melanoma cell lines into NOD/SCID gamma mice. We assessed the immunohistochemical expression of IMP3, E-cadherin, N-cadherin, PARP1, HIF-1α, and the proliferation marker Ki-67. Additionally, we performed a retrospective study including 114 histological samples of patients diagnosed with malignant cutaneous Superficial Spreading Melanoma, and Nodular Melanoma with at least five years of follow-up. Results: Most morphological and immunohistochemical features show statistically significant differences between the two cell lines. All three treatments reduced the cell proliferation evaluated by the Ki-67 nuclear antigen (P=0.000) and reduced the number of metastases (P=0.004). In addition, the tumor volumes reduced in comparison with the control groups, 31.74% for RT+MSCs in the A357 tumor cell line, and 89.84% RT+MSCs in the G361 tumor cell line. We also found that IMP3 expression is associated with greater tumor aggressiveness and was significantly correlated with cell proliferation, the number of metastases, and reduced expression of adhesion molecules. Discussion/Conclusions: The combined treatment of RT+MSCs on xenografted melanomas reduces tumor size, metastases frequency and the EMT/PARP1 metastatic phenotype. This treatment also reduces the expression of molecules related to cellular proliferation (Ki-67), molecules that facilitate the metastatic process (E-cadherin) and molecules related with prognosis (IMP3).

show abstract

Section: Discussionsupporting

confidence: 90%

IMP3 Immunohistochemical Expression Is Related with Progression and Metastases in Xenografted and Cutaneous Melanomas

Martin-Morales,

Padial-Molina,

Tovar

et al. 2023

Pathobiology

View full text Add to dashboard Cite

show abstract

“…In pathological conditions, the expression of IMP3 is elevated in various malignant tumors (7). In addition, there were researches demonstrating that the possibility of distant carcinoma metastasis was associated with unfavorable prognosis (12)(13)(14)(15). DEK is a new member of DNA topology adjustment factors (10).…”

Section: Discussionmentioning

confidence: 99%

Epithelial‑mesenchymal transition in colorectal carcinoma cells is mediated by DEK/IMP3

Shang

Guan

2017

Mol Med Report

View full text Add to dashboard Cite

To investigate the inhibitory effects of DEK/insulin‑like growth factor II mRNA binding protein 3 (IMP3) on epithelial‑mesenchymal transition (EMT) in colorectal carcinoma cells. SW620 and SW480 cell lines were selected. DEK‑interfering lentivirus was transfected to knockdown DEK expression. Subsequently, MTT assays and flow cytometry were utilized to measure cell viability, and apoptosis, respectively. Cell invasion was detected using a Transwell assay. Quantitative polymerase chain reaction and western blot analysis were used to detect the expression of E‑cadherin, vimentin, and matrix metalloproteinase (MMP)‑9. Compared with the blank control, cells transfected with DEK‑interfering lentivirus demonstrated a remarkable reduction in cell viability (P<0.05). The apoptotic rate in the DEK‑interfering lentivirus group was significantly enhanced compared with the blank control group (P<0.05). In the DEK‑interfering lentivirus group, the expression of E‑cadherin was significantly elevated (P<0.05), while the expression of vimentin and MMP‑9 were significantly reduced in both cell lines (P<0.05). The results of the present study demonstrated that EMT of colorectal carcinoma cells was partially mediated by DEK, which likely affected the invasive ability of colorectal carcinoma cells. In addition, cell proliferation and apoptosis were susceptible to DEK silencing. The current study has provided experimental evidence for the treatment of colorectal carcinoma using DEK silencing.

show abstract

“…Similar to VEGF-A, the results on the correlation between IMP3 expression and survival are also conflicting. Some studies identified IMP3 as an independent risk factor for poor prognosis in lung cancer and renal cell carcinoma patients (42–44). However, in the present study, the difference in survival time between the IMP3-positive and negative groups was not statistically significant, as reported by another previous study (41).…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of insulin‑like growth factor 2 mRNA‑binding protein 3 and vascular endothelial growth factor‑A in patients with primary non‑small‑cell lung cancer

Liu

Gong

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

Insulin-like growth factor 2 mRNA-binding protein 3 (IMP3) and vascular endothelial growth factor-A (VEGF-A) may play important roles in the process of tumor progression and tumor angiogenesis. The aim of the present study was to examine the co-expression of IMP3 and VEGF-A in primary human non-small cell lung cancer (NSCLC), to investigate the association between these two expression levels and determine the clinicopathological implications, including changes to microvessel density (MVD), and to assess the prognostic value of co-expression. Using immunohistochemical staining, the expression of IMP3, VEGF-A and CD34 expression was detected in 128 primary NSCLC tissue samples. According to the expression of IMP3 and VEGF-A, the cases were divided into four groups. Next, the clinicopathological features, MVD and survival time were investigated across the different groups. The immunohistochemical analyses demonstrated that there was a significant correlation between IMP3 and VEGF-A expression in NSCLC (r=0.181; P=0.041). Co-expression of IMP3 and VEGF-A was significantly associated with larger primary tumor size (P=0.016), poorer differentiation (P=0.014), more advanced Tumor-Node-Metastasis stage (P=0.012), increased MVD (P=0.004) and positive lymph node metastasis (P=0.002). Survival analysis demonstrated that cases with IMP3 and VEGF-A double-positive staining were significantly associated with lower survival rates compared with cases with double-negative staining (P=0.039). In the early NSCLC (I–IIa) subgroup, the mean survival time of the double-positive staining group was significantly shorter compared with that of the double-negative staining group (P=0.015). Co-expression of IMP3 and VEGF-A was associated with angiogenesis and a poorer prognosis in NSCLC, and may therefore play a critical role in NSCLC progression.

show abstract

IMP3, a Promising Prognostic Marker in Clear Cell Renal Cell Carcinoma

Cited by 7 publications

References 25 publications

IMP3 Immunohistochemical Expression Is Related with Progression and Metastases in Xenografted and Cutaneous Melanomas

IMP3 Immunohistochemical Expression Is Related with Progression and Metastases in Xenografted and Cutaneous Melanomas

Epithelial‑mesenchymal transition in colorectal carcinoma cells is mediated by DEK/IMP3

Prognostic value of insulin‑like growth factor 2 mRNA‑binding protein 3 and vascular endothelial growth factor‑A in patients with primary non‑small‑cell lung cancer

Contact Info

Product

Resources

About